The Global Health Body Issues Alert Over Critical Lack of Obesity Jabs
Fewer than 10% of patients eligible to benefit from GLP-1 drugs including Wegovy are able to get them, warns the global health agency as it releases its first recommendations on the medications.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for more widespread and fairer access to GLP-1 medication.
Per estimates, more than two billion could be obese by 2030 unless action is taken.
"Our latest guidance affirms that obesity is a lifelong illness that can be managed with holistic and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are key obstacles to widespread access to the jabs that can assist patients in reducing considerable weight, notes the agency.
GLP-1 Therapy Shortage
Even under the current best projected case, the supply of GLP-1 therapies would only suffice for approximately 100 million people – fewer than 10% of eligible patients, per the health organization.
The recommendation urges governments and firms to widen access, via approaches such as licensing agreements.
A patent on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in multiple nations in 2026.
The Way Obesity Drugs Work
GLP-1 drugs replicate a biological compound to slow digestion, suppress the appetite and enhance the sense of being full so individuals consume fewer calories.
Individuals usually see weight reduction after several weeks of commencing the regular doses.
Research indicates people may regain a significant portion a year later of discontinuing the treatment, because their typical hunger come back.
Being carrying excess weight increases your likelihood for experiencing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity affects individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
